OraVerse is a unique, local anesthetic reversal agent that accelerates the return to normal sensation and function for patients who want to avoid unwanted and unnecessary lingering soft tissue anesthesia.
OraVerse has been proven safe and effective for adults and children 6 and older and weighing more than 33 lbs in nationwide clinical trials involving 636 patients. Patients who received OraVerse experienced a return to normal sensation and function in approximately half the time. OraVerse comes in a standard dental cartridge and is administered in a 1:1 ratio to local anesthetic.
The majority of adverse events were mild and resolved within 48 hours. Tachycardia, bradycardia, and cardiac arrhythmias may occur with the use of phentolamine or other alpha-adrenergic blocking agents. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of these events, particularly in patients with a history of cardiovascular disease.
Following parenteral use of phentolamine at doses between 5 to 15 times higher than the recommended dose of OraVerse, myocardial infarction, and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states.
